Both patients with rhabdomyosarcoma and actionable somatic gain-of-function mutations predicting response to mTOR inhibition achieved CR to temsirolimus with vinorelbine and cyclophosphamide, compared to 5 of 42 participants who achieved CR in the molecularly unselected pediatric phase II study arm39. This evidence concerns the gene MTOR and rhabdomyosarcoma.